Tuomo

Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting

Retrieved on: 
Friday, September 22, 2023
Tuomo, AIM, Option, EGM, Nasdaq First North, Cancer

TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the "EGM") of the Company took place today, September 22, 2023 in Turku, Finland.

Key Points: 
  • TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the "EGM") of the Company took place today, September 22, 2023 in Turku, Finland.
  • The EGM approved all proposals of the Board of Directors ("Board") as set out in the notice of the EGM published on September 1, 2023.
  • Christine Roth and Marie-Louise Fjällskog were elected as new members to the Board for a term that ends at the end of the next annual general meeting.
  • The amendment applies to all options under the Option Plan 2015 (A options, B options, C options and D options).

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

Retrieved on: 
Tuesday, August 29, 2023
Faron Pharmaceuticals, MCR, Survival, HMA, Bone marrow, Head, MBA, Congress, Nasdaq First North, Patient, MedRxiv, Majesty of the Seas, Executive, AIM, European Hematology Association, NK, Manuscript, Celgene, ORS, PD-1, FDA, IPF, Venetoclax, ODD, Cancer, American Association for Cancer Research, Immunotherapy, Antigen presentation, Biomarker, CR, Tuomo, Bristol Myers Squibb, MDS, EUR, AML, Azacitidine, CPA, Tumor microenvironment, Lithium, Pharmaceutical industry, Vaccine, Management, Security (finance), Rare-earth element, Medical imaging, Fårö, Phase, SOC

TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").

Key Points: 
  • Mr. Leopoldo Zambeletti stepped down from the Board to assume a business development consulting role at Faron.
  • TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").
  • "I am extremely proud of the progress we made in the first half of 2023,” said Dr. Markku Jalkanen, Chief Executive Officer of Faron.
  • On June 30, 2023, the Company had outstanding borrowings of EUR 9.8 million under a loan facility with IPF Partners which is subject to financial covenants.

Picosun Congratulates Dr. Tuomo Suntola on the Millennium Technology Prize 2018

Retrieved on: 
Tuesday, May 22, 2018
Thin film deposition, Tuomo Suntola, Semiconductor device fabrication, Atomic layer deposition, ALD, Tuomo, Millennium Technology Prize, Poutiainen, Science and technology, Culture, Innovation

ESPOO, Finland, May 22, 2018 /PRNewswire/ --Dr. Tuomo Suntola, the inventor of ALD and Picosun Board member, has received the Millennium Technology Prize 2018 .

Key Points: 
  • ESPOO, Finland, May 22, 2018 /PRNewswire/ --Dr. Tuomo Suntola, the inventor of ALD and Picosun Board member, has received the Millennium Technology Prize 2018 .
  • He saw the huge potential of atomic layer deposition and thin-film technology in microelectronics and information technology," says Pivi Trm, Chair of the Board of the Millennium Technology Prize Selection Committee.
  • Tuomo is an incredible innovator, who has definitely deserved this prize.
  • At Picosun, it is our obligation to Tuomo to keep spearheading the development of ALD, as an agile and innovation-driven company," says Poutiainen.

Picosun Congratulates Dr. Tuomo Suntola on the Millennium Technology Prize 2018

Retrieved on: 
Tuesday, May 22, 2018
Thin film deposition, Tuomo Suntola, Semiconductor device fabrication, Atomic layer deposition, ALD, Tuomo, Millennium Technology Prize, Poutiainen, Science and technology, Culture, Innovation

ESPOO, Finland, May 22, 2018 /PRNewswire/ --Dr. Tuomo Suntola, the inventor of ALD and Picosun Board member, has received the Millennium Technology Prize 2018 .

Key Points: 
  • ESPOO, Finland, May 22, 2018 /PRNewswire/ --Dr. Tuomo Suntola, the inventor of ALD and Picosun Board member, has received the Millennium Technology Prize 2018 .
  • He saw the huge potential of atomic layer deposition and thin-film technology in microelectronics and information technology," says Pivi Trm, Chair of the Board of the Millennium Technology Prize Selection Committee.
  • Tuomo is an incredible innovator, who has definitely deserved this prize.
  • At Picosun, it is our obligation to Tuomo to keep spearheading the development of ALD, as an agile and innovation-driven company," says Poutiainen.